- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00817037
Sitaxsentan in Proteinuric Chronic Kidney Disease
The Effect of Sitaxsentan Once Daily Dosing on Proteinuria, 24-Hour Systemic Blood Pressure, and Arterial Stiffness in Subjects With Chronic Kidney Disease
Patients with chronic kidney disease (CKD) have higher blood pressures than the general population. They also tend to have protein leaking into the urine (proteinuria). CKD, high blood pressure and proteinuria independently and together increase the risk of developing atherosclerosis (hardening) of the arteries that leads to diseases such as heart attack and stroke. Although there are a number of drugs available that lower blood pressure, these are not always fully effective. Furthermore, there are even fewer drugs that simultaneously lower blood pressure, reduce proteinuria, and slow down kidney damage in CKD.
Recent research has shown that drugs like sitaxsentan not only lower blood pressure but also reduce proteinuria and potentially slow down the progression of CKD [1,2]. Before sitaxsentan can become freely available to individuals with CKD it is important to look at the effects this drug could have on proteinuria and blood pressure.
- Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-1193.
- Krum H, Viskoper RJ, Lacourciere Y et al. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New Engl J Med 1998;338:784-790.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH4 2XU
- Clinical Research Centre, Western General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has Stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (using the Cockcroft and Gault equation for calculation of glomerular filtration rate) with proteinuria, including any of the following aetiologies: immunoglobulin A (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy.
- Is between 18 and 70 years of age, inclusive.
- Has a body mass index (BMI) between 18 and 35 kg/m2, inclusive.
- Is willing and able to adhere to the protocol requirements.
- Provides written informed consent before any study procedure is performed.
Exclusion Criteria:
- Requires peritoneal dialysis or haemodialysis.
- Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.
- Has a serum albumin in the nephrotic range (< 30 g/L) during Screening.
- Has a sustained sitting systolic blood pressure (BP) > 160 mmHg or sustained sitting diastolic BP > 100 mmHg during Screening.
- Has postural hypotension during Screening, which is defined as a decrease in systolic BP ≥ 20 mmHg and/or a decrease in diastolic BP ≥ 10 mmHg, comparing sitting and standing measurements.
- Has a history and/or evidence of ischaemic heart disease.
- Has or had a malignancy, with the exception of adequately-treated basal cell or squamous cell carcinoma of the skin, that required significant medical intervention within the past 3 months and/or is likely to result in death within the next 2 years.
- Has a history of allergies or hypersensitivity to sitaxsentan or nifedipine or the excipients of either drug.
- Has a clinically significant psychiatric, addictive, neurological disease or any other condition that, in the Investigator's opinion, would compromise his/her ability to give informed consent, participate fully in this study, prevent adherence to the requirements of the study protocol, or would compromise the interpretation of the data obtained from this study.
Uses a prohibited medication or plans to use a prohibited medication during the study.
- Prohibited medications include cyclosporine A, alternative endothelin (ET) receptor antagonists, phosphodiesterase inhibitors, and/or vitamin K antagonists (e.g., warfarin). The intermittent use of phosphodiesterase inhibitors (e.g., sildenafil) "as needed" for erectile dysfunction is acceptable, however, as long as the subject is not dosed within 24 hours of an efficacy assessment.
- Received treatment with an investigational drug or device within 30 days prior to study entry.
- Has a history of organ transplantation.
- Has atrial fibrillation requiring anticoagulation or a history (in the preceding 6 months) of any intermittent cardiac dysrhythmia that may require anticoagulation therapy.
- Has an alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) level > 1.5 × the upper limit of the normal range (ULN) at Screening and/or serum total bilirubin > ULN.
- Has a haemoglobin concentration < 8.0 mg/dL at Screening.
- Has positive serological results for hepatitis B and/or hepatitis C.
- Is a woman of childbearing potential who is unwilling to use 2 forms of contraceptive therapy, including at least 1 barrier method, throughout the study. (Women who are surgically sterile or who are post-menopausal for at least 2 years are not considered to be of childbearing potential.)
- Is pregnant, lactating, or breastfeeding.
- Has, in the opinion of the Investigator, a dependence on alcohol.
- Has, in the opinion of the Investigator, a dependence on illicit drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sitaxsentan
Once daily oral sitaxsentan 100mg given over a period of 6 weeks. 24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment |
Sitaxsentan 100mg once daily oral dosing for 6 weeks
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Once daily oral placebo tablet given over a period of 6 weeks. 24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment |
Placebo tablet once daily oral dosing for 6 weeks
|
ACTIVE_COMPARATOR: Nifedipine
Open labeled active comparator Once daily oral nifedipine 30mg given over a period of 6 weeks. 24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment |
Nifedipine 30mg once daily oral dosing for 6 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The principal objective of this study is to evaluate whether sitaxsentan reduces proteinuria in people with chronic kidney disease.
Time Frame: 6 Weeks
|
6 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary objective of this study is to evaluate whether sitaxsentan reduces systemic blood pressure in people with chronic kidney disease.
Time Frame: 6 weeks
|
6 weeks
|
Secondary objective is to determine whether sitaxsentan improves indices of arterial stiffness in people with chronic kidney disease
Time Frame: 6 weeks
|
6 weeks
|
Secondary objectives is to determine the safety of sitaxsentan in chronic kidney disease
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: David Webb, MD DSc FRCP FRSE FMedSci, University of Edinburgh
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Urological Manifestations
- Renal Insufficiency
- Urination Disorders
- Kidney Diseases
- Renal Insufficiency, Chronic
- Proteinuria
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Endothelin Receptor Antagonists
- Nifedipine
- Sitaxsentan
Other Study ID Numbers
- 2007/W/CRC/02
- CTA# 2006-002004-33
- 06/MRE10/69
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Proteinuria
-
Universiteit AntwerpenCompleted
-
University of Sao PauloCompleted
-
Nantes University HospitalTerminated
-
Marshall UniversityUniversity at BuffaloRecruiting
-
Greater Boston Medical AssociatesMassachusetts General HospitalUnknownDecrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte FunctionUnited States
-
Gulhane School of MedicineCompletedWe Searched for the Effects of Calcium Channel Blocker Amlodipine on the Clinical and Laboratory Parameters of Diabetic Patients With Proteinuria.Turkey
-
University of Mississippi Medical CenterCompletedPregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) | Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe) | Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia)United States
-
Zekai Tahir Burak Women's Health Research and Education...UnknownBasal Proteinuria in PregnancyTurkey
-
Brigham and Women's HospitalBristol-Myers SquibbCompleted
-
Xinhua Hospital, Shanghai Jiao Tong University...Unknown
Clinical Trials on Sitaxsentan
-
PfizerCompletedCardiac Surgery Subjects | Subjects Undergoing CABG and/or Cardiac Valve ReplacementUnited States
-
VA Office of Research and DevelopmentMedical University of South CarolinaCompleted
-
ICOS-Texas BiotechnologyICOS Corporation; Texas Biotechnology CorporationUnknownPulmonary HypertensionUnited States, Canada
-
Encysive PharmaceuticalsCompletedPulmonary HypertensionUnited States
-
PfizerTerminatedPulmonary Arterial Hypertension | Pulmonary HypertensionUnited States, Bulgaria, Argentina, Chile, China, Colombia, Costa Rica, Czech Republic, Dominican Republic, Guatemala, India, Malaysia, Mexico, Peru, Philippines, Romania, Russian Federation, Saudi Arabia, Serbia, Slovakia, South... and more
-
PfizerTerminatedPulmonary Arterial Hypertension | Pulmonary HypertensionUnited States, Romania, Ukraine
-
PfizerTerminatedHypertension, PulmonaryJapan
-
PfizerTerminatedPulmonary Arterial Hypertension | Pulmonary HypertensionUnited States, Bulgaria, Argentina, Chile, China, Colombia, Czech Republic, India, Malaysia, Mexico, Peru, Romania, Russian Federation, Serbia, South Africa, Thailand, Turkey, Ukraine
-
PfizerTerminatedHypertension, PulmonaryJapan
-
PfizerTerminatedPulmonary Arterial HypertensionUnited States, Netherlands, Canada, Belgium, France, Germany, Italy, Spain, United Kingdom, Australia, Poland, Austria, Brazil, Israel, Argentina, Mexico